Industry Trends

The redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.

2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.

In a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.

If telehealth is here to stay, how is the industry adjusting?

What the industry has learned navigating the pandemic and what the future holds for field teams.

Cliodhna McDonough and Emily Lockey give a UK perspective on the potential pros and cons of the three leading candidates in the COVID-19 vaccine race.

In unveiling a set of drug price control measures last week, the president displayed his bitterness that vaccine makers failed to announce their success in achieving high efficacy rates for new preventives before the Nov. 3 election.

A brief look into how the Gene Editing Institute researching the diversity of responses in African-American regenerative cells to various forms of CRISPR.

Authorities fear distrust of early preventives and complications for ongoing COVID-19 research.

Must maintain trust in face of customary, non-pandemic challenges.

Lessons to launch by during a pandemic—or otherwise.

President-elect Biden has announced initiatives to combat the widening coronavirus pandemic including a 13-member COVID advisory board.

Lise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.

The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role 
in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.

Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.

FDA has published updated Emergency Use Authorization (EUA) requirements for new coronavirus preventives.

Experts fear confusion over allocation process, cold-chain requirements, IT systems.

Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.

To effectively lead in today’s unpredictable environment, several major pharma companies are turning to a neuroscience-based learning approach to leadership development.

Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.

With all eyes on efforts to research and test potential vaccines and therapies to combat the coronavirus pandemic, fears about overly accelerated development programs has heightened demands for wider access to information on study protocols, statistical analysis plans, and early results.

President Trump has taken on the pharma industry in a surprise move making significant cuts in reimbursement for drugs covered by Medicare.

Amid pandemic, rely on the fundamentals.